Benralizumab in the Treatment of Patients With Severe Asthma With ABPA
Palo Alto (17 mi)Overseen byYolanda Mageto, MD
Age: 18+
Sex: Any
Travel: May be covered
Time Reimbursement: Varies
Trial Phase: Phase 4
Waitlist Available
Sponsor: Baylor Research Institute
No Placebo Group
Prior Safety Data
Approved in 4 jurisdictions
Trial Summary
What is the purpose of this trial?This trial will test benralizumab injections in patients with severe asthma and ABPA. Benralizumab helps by reducing certain immune cells that cause inflammation. The treatment involves several injections over a few months, with follow-up visits to monitor progress.
Eligibility Criteria
Treatment Details
1Treatment groups
Experimental Treatment
Group I: TreatmentExperimental Treatment1 Intervention
Benralizumab treatment will be given by injections administered every 4 weeks for the first 3 injections with an additional injection eight weeks to follow for a total of 16 weeks active treatment
Benralizumab is already approved in European Union, United States, Canada, Japan for the following indications:
🇪🇺 Approved in European Union as Fasenra for:
- Severe eosinophilic asthma
🇺🇸 Approved in United States as Fasenra for:
- Severe asthma with an eosinophilic phenotype
🇨🇦 Approved in Canada as Fasenra for:
- Severe eosinophilic asthma
🇯🇵 Approved in Japan as Fasenra for:
- Severe eosinophilic asthma
Find a clinic near you
Research locations nearbySelect from list below to view details:
Baylor University Medical CenterDallas, TX
Loading ...
Who is running the clinical trial?
Baylor Research InstituteLead Sponsor